CATALENTAI
Live / Applied — New application — not yet assigned to an examiner (as of 20 Jan 2026)
What this means for you
Not registered yet, but its 20 Jan 2026 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 99603372
- Mark type
- Stylized text
- Filed
- 20 Jan 2026
- Attorney of record
- Vanessa A. Ignacio, Esq.
Goods and services
- Class 042 — Scientific and technological services: Software as a service (SAAS) services featuring software using artificial intelligence (AI) for incident management and deviation management; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for incident management and deviation management; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for investigating, resolving deviation life cycle management, root cause analysis management, deviation tracking and reporting management, audit management, change control management, complaint and investigations management, and product annual review management; Quality management services, namely, quality evaluation and analysis, quality assurance, and quality control, in the field of drug development for pharmaceutical and biotech industries; Software as a service (SAAS) services featuring software using artificial intelligence (AI) for providing quality evaluation and analysis, quality assurance, and quality control, in the field of drug development for pharmaceutical and biotech industries; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for deviation management, risk assessment, and root cause analysis; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for deviation management in regulated manufacturing environments; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for workflow automation of deviation lifecycle processes, namely, initiation, review, approval, corrective and preventive actions (CAPA), and closure; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for audit preparation and support, namely, compiling compliance documentation, and generating audit ready reports; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for change control management, namely, initiating, routing, approving, and implementing changes; Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for complaints handling and investigations support, namely, intake, triage, root cause analysis, and corrective and preventive actions (CAPA); Artificial intelligence as a service (AIAAS) services featuring software using artificial intelligence (AI) for product annual review support, namely, aggregating production and quality data, trend analysis, and generating annual product review reports; Pharmaceutical drug development services; Pharmaceutical research and development; Product development in the field of pharmaceuticals, biopharmaceuticals, radiopharmaceuticals, pharmaceutical preparations, vitamins, medicines, pharmaceutical packaging and drug delivery technologies; Research and development of new products for others; Product development consultation; Scientific research consulting in the field of pharmaceuticals and biopharmaceuticals; Technology consultation in the field of pharmaceuticals and new drug development; Custom design and development of chemical reagents and biochemical assays; Development of pharmaceuticals for cell and gene therapies; Research and development and consultation related thereto in the field of over-the-counter drugs; Research and development in the field of pharmaceutical preparations and products for cell therapy, gene therapy, and beauty care; Scientific research consulting; Technology consultation in the field of new drug development for the pharmaceutical industry; Technology consultation in the field of pharmaceutical drug delivery and dosage technologies; Scientific research consulting in the field of pharmaceutical drug delivery and dosage technologies; Testing of pharmaceuticals
Owner
- R.P. SCHERER TECHNOLOGIES, LLC, Bridgewater, NJ, US
Prior registrations
Prosecution history
- 20 Jan 2026 — APPLICATION FILING RECEIPT MAILED
- 20 Jan 2026 — NEW APPLICATION ENTERED